Diagnosis and Emerging Treatment Strategies for Mucopolysaccharidosis VII (Sly Syndrome)
- PMID: 36578769
- PMCID: PMC9791935
- DOI: 10.2147/TCRM.S351300
Diagnosis and Emerging Treatment Strategies for Mucopolysaccharidosis VII (Sly Syndrome)
Abstract
Mucopolysaccharidosis VII (MPS VII, Sly syndrome) is an ultra-rare lysosomal disease caused by a deficiency of the enzyme β-glucuronidase (GUS). The diagnosis is suspected based on a range of symptoms that are common to many other MPS types, and it is confirmed through biochemical and molecular studies. Besides supportive treatment, current and emerging treatments include enzyme replacement therapy, hematopoietic stem cell transplantation, and gene therapy. This review summarizes the clinical manifestations, diagnosis, and emerging treatments for MPS VII.
Keywords: Sly syndrome; enzyme replacement therapy; gene therapy; hematopoietic stem cell transplantation; lysosomal disorders; mucopolysaccharidosis type VII.
© 2022 Poswar et al.
Conflict of interest statement
The authors report no conflicts of interest related to this work.
Figures
References
-
- Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Valle DL, Antonarakis S, Ballabio A, Beaudet AL, Michell GA, editors. The Online Metabolic and Molecular Bases of Inherited Disease. McGraw Hill; 2007.
Publication types
LinkOut - more resources
Full Text Sources
